Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Valneva SE - American Depositary Shares (NQ:VALN)

9.679 +0.189 (+1.99%)
Streaming Delayed Price Updated: 3:16 PM EST, Feb 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Valneva SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
VALN Investors Have Opportunity to Join Valneva SE Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
News headline image
4 Analysts Have This To Say About Valneva ↗
 
Via Benzinga
News headline image
Expert Ratings For Valneva ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 6 Analyst Recommendations For Valneva ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
From Pomerantz LLP
Via GlobeNewswire
News headline image
Breaking Down Valneva: 6 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot ↗
Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions. 
Via Benzinga
News headline image
The Analyst Landscape: 6 Takes On Valneva ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 8 Ratings For Valneva ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Valneva Stock ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 6 Takes On Valneva ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 20, 2025 ↗
 
Via Benzinga
News headline image
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Valneva Stock ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Valneva ↗
 
Via Benzinga
News headline image
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults ↗
Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts. 
Via Benzinga
News headline image
European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
News headline image
Palo Alto Networks To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study ↗
Valneva and Pfizer released data from their Phase 2 study of the Lyme disease vaccine candidate VLA15, showing strong immune response and safety profile after a second booster dose, with seroconversion... 
Via Benzinga
News headline image
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q2 2024 ↗
VALN stock results show that Valneva missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
3 Promising Biotech Stocks You Can Pick Up for Less Than $10 ↗
Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price. 
Via InvestorPlace
News headline image
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026 ↗
Pfizer and Valneva announced the completion of the primary vaccination series in the Phase 3 VALOR trial for their Lyme disease vaccine, VLA15. Participants will be monitored until the end of the 2025... 
Via Benzinga
News headline image
Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data ↗
Valneva released positive Phase 3 data for its single-shot chikungunya virus vaccine in adolescents. The vaccine is also expected to be approved for use in Brazil. 
Via Benzinga
News headline image
VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q1 2024 ↗
VALN stock results show that Valneva missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.